title: Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease.
abstract: Available data and models for the health-economic evaluation of treatment in Alzheimer's disease (AD) have limitations causing uncertainty to decision makers. Forthcoming treatment strategies in preclinical or early AD warrant an update on the challenges associated with their economic evaluation. The perspectives of the co-authors were complemented with a targeted review of literature discussing methodological issues and data gaps in AD health-economic modelling. The methods and data available to translate treatment efficacy in early disease into long-term outcomes of relevance to policy makers and payers are limited. Current long-term large-scale data accurately representing the continuous, multifaceted, and heterogeneous disease process are missing. The potential effect of disease-modifying treatment on key long-term outcomes such as institutionalization and death is uncertain but may have great effect on cost-effectiveness. Future research should give priority to collaborative efforts to access better data on the natural progression of AD and its association with key long-term outcomes.
authors.affiliation: Quantify Research, Stockholm, Sweden; Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. Electronic address: anders.gustavsson@quantifyresearch.com.
authors.forename: Anders
authors.initials: A
authors.lastname: Gustavsson
authors.affiliation: University of Exeter Medical School, University of Exeter, Exeter, UK.
authors.forename: Colin
authors.initials: C
authors.lastname: Green
authors.affiliation: RICE-The Research Institute for the Care of Older People, Royal United Hospital, Bath, UK.
authors.forename: Roy W
authors.initials: RW
authors.lastname: Jones
authors.affiliation: Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.
authors.forename: Hans
authors.initials: H
authors.lastname: Förstl
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Deniz
authors.initials: D
authors.lastname: Simsek
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Frederic
authors.initials: F
authors.lastname: de Reydet de Vulpillieres
authors.affiliation: Quantify Research, Stockholm, Sweden.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Luthman
authors.affiliation: Novartis Pharmaceuticals UK Limited, Camberley, UK.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Adlard
authors.affiliation: Novartis Healthcare Private Limited, Hyderabad, India.
authors.forename: Subrata
authors.initials: S
authors.lastname: Bhattacharyya
authors.affiliation: Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Wimo
mesh_terms: D000544:Alzheimer Disease / Q000191:economics* / Q000628:therapy*; D000818:Animals; D035843:Biomedical Research / Q000379:methods / Q000639:trends; D003362:Cost-Benefit Analysis / Q000379:methods*; D018450:Disease Progression; D006801:Humans; D018803:Models, Economic
keywords: Alzheimer's disease; Cost-effectiveness; Dementia; Disease modification; Disease progression; Economic evaluation; Health care decision making; Modelling; Outcomes; Preclinical